Q-omics provides the consensus-scored STPG2 profile across patient tissues and cancer cell-line models. STPG2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, STPG2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, STPG2 RNA expression shows 17,702 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUSC, KIRC, and THYM as cancer lineages where STPG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STPG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STPG2 survival associations across molecular data types. STPG2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STPG2 RNA expression–survival associations across cancer types. High STPG2 expression shows unfavorable associations in LUSC, THCA, KICH and KIRP, but favorable associations in READ and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for STPG2 RNA expression.
This table summarizes STPG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for STPG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STPG2 shows lower tumor expression in KIRC, KIRP, THCA, KICH and UCEC and higher tumor expression in HNSC. The KIRC box plot shows higher STPG2 RNA expression in normal versus tumor tissue (log2 FC = −0.350, t-test p < 0.001).
This table shows molecular features associated with STPG2 in patient tissues and cancer cell lines. In patient samples, STPG2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, STPG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_SCLC.
